The New England journal of medicine
-
Editorial Comment
Givosiran - Running RNA Interference to Fight Porphyria Attacks.
-
Comment Letter
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
-
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. ⋯ In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).